Deniz GÜRER, Fatma TOKGÖZ AKYIL, Mustafa AKYIL, Çağatay TEZEL, Serdar EVMAN, Levent ALPAY, Volkan BAYSUNGUR, İrfan YALÇINKAYA

Küçük hücreli dışı akciğer kanserinde neoadjuvan tedavi sonrası patolojik tam yanıtın prognostik önemi

Amaç: Bu çalışmada cerrahi rezeksiyon yapılan küçük hücreli dışı akciğer kanserli hastalarda neoadjuvan tedavi sonrası patolojik tam yanıt ile ilişkili faktörler araştırıldı ve patolojik tam yanıtın prognostik değeri incelendi. Çalışma planı: Şubat 2009 - Ocak 2016 tarihleri arasında küçük hücreli dışı akciğer kanseri tanısı konulan ve neoadjuvan tedavi sonrasında anatomik pulmoner rezeksiyon yapılan toplam 112 hasta (96 erkek, 16 kadın; ort. yaş 60±8 yıl; dağılım, 37-85 yıl) retrospektif olarak incelendi. Hastaların demografik, klinik, radyolojik ve patolojik özellikleri kaydedildi. Hastalar patoloji raporunda tümör varlığına göre patolojik tam yanıt ve patolojik tam yanıt olmayanlar olmak üzere sınıflandırıldı. Patolojik tam yanıtın öngördürücü faktörleri ve prognostik önemi incelendi. Bulgular: Ortalama takip süresi 35±20 (dağılım, 0-110) ay idi. Hastaların 30’unda (%27) patolojik tam yanıt elde edildi. Tümör boyutunda görülen küçülme oranı, yanıt veren grupta anlamlı düzeyde daha yüksek olup (sırasıyla %19.2±18.8’e kıyasla %32.5±21.6), T ve N faktörlerinden bağımsız olarak, patolojik tam yanıtın bir öngördürücü idi (p=0.004). Yanıt veren hastaların sağkalım süresi, yanıt vermeyenlere kıyasla anlamlı düzeyde daha uzundu (sırasıyla, 30±4 aya kıyasla 75±9 ay, p

Prognostic significance of pathological complete response in non-small cell lung cancer following neoadjuvant treatment

Background: This study aims to investigate the factors associated withpathological complete response following neoadjuvant treatment andto examine the prognostic value of pathological complete response inpatients with non-small cell lung cancer undergoing surgical resection.Methods: Between February 2009 and January 2016, a total of 112patients (96 males, 16 females; mean age 60±8 years; range, 37 to 85years) with the diagnosis of non-small cell lung cancer who underwentanatomical pulmonary resection after neoadjuvant treatment wereretrospectively analyzed. Demographic, clinical, radiological, andpathological characteristics of the patients were recorded. Thepatients were classified as pathological complete response and nonpathologicalcomplete response according to the presence of tumorsin the pathology reports. Predictive factors for pathological completeresponse and its prognostic significance were analyzed.Results: The mean follow-up was 35±20 (range, 0 to 110) months.Of the patients, 30 (27%) achieved a pathological complete response.Reduction rate in tumor size was significantly higher in theresponsive group (32.5±21.6% vs. 19.2±18.8%, respectively) andwas a predictor of pathological complete response independentfrom the T and N factors (p=0.004). Survival of the responsivepatients was significantly longer than unresponsive patients(75±9 vs. 30±4 months, respectively; p

PDF

___

1. World Health Organization. International Agency for Research on Cancer (IARC) GLOBOCAN 2012. Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: globocan.iarc.fr/Pages/fact_sheets_cancer.aspx
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
3. Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, et al. Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manag Res 2019;11:943-53.
4. Subramanian J, Regenbogen T, Nagaraj G, Lane A, Devarakonda S, Zhou G, et al. Review of ongoing clinical trials in non-small-cell lung cancer: a status report for 2012 from the ClinicalTrials.gov Web site. J Thorac Oncol 2013;8:860-5.
5. Lewis J, Gillaspie EA, Osmundson EC, Horn L. Before or After: Evolving neoadjuvant approaches to locally advanced non-small cell lung cancer. Front Oncol 2018;8:5.
6. Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C, et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 2009;374:379-86.
7. Shah AA, Berry MF, Tzao C, Gandhi M, Worni M, Pietrobon R, et al. Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. Ann Thorac Surg 2012;93:1807-12.
8. Bharat AGB, Rusch VW, Bains MS, Rizk NP. Role of PET scan in predicting response to neoadjuvant chemotherapy and long-term outcome for stage II cancer. ASCO Meet Abstr 2014;32(15 suppl):7574.
9. Blumenthal GM, Bunn PA Jr, Chaft JE, McCoach CE, Perez EA, Scagliotti GV, et al. Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. J Thorac Oncol 2018;13:1818-31.
10. Coroller TP, Agrawal V, Narayan V, Hou Y, Grossmann P, Lee SW, et al. Radiomic phenotype features predict pathological response in non-small cell lung cancer. Radiother Oncol 2016;119:480-6.
11. Mouillet G, Monnet E, Milleron B, Puyraveau M, Quoix E, David P, et al. Pathologic complete response to preoperative chemotherapy predicts cure in early-stage non-small-cell lung cancer: combined analysis of two IFCT randomized trials. J Thorac Oncol 2012;7:841-9.
12. Betticher DC, Hsu Schmitz SF, Tötsch M, Hansen E, Joss C, von Briel C, et al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-smallcell lung cancer: 5-year follow-up of a phase II study. Br J Cancer 2006;94:1099-106.
13. Katakami N, Tada H, Mitsudomi T, Kudoh S, Senba H, Matsui K, et al. A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903). Cancer 2012;118:6126-35.
14. Melek H, Çetinkaya G, Özer E, Yentürk E, Sevinç TE, Bayram AS, et al. Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?†. Eur J Cardiothorac Surg 2019;56:604-11.
15. Pisters KM, Kris MG, Gralla RJ, Zaman MB, Heelan RT, Martini N. Pathologic complete response in advanced non-small-cell lung cancer following preoperative chemotherapy: implications for the design of future nonsmall- cell lung cancer combined modality trials. J Clin Oncol 1993;11:1757-62.
16. Qu Y, Emoto K, Eguchi T, Aly RG, Zheng H, Chaft JE, et al. Pathologic assessment after neoadjuvant chemotherapy for NSCLC: importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma. J Thorac Oncol 2019;14:482-93.
17. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2:706-14.
18. Available at: www.obs.gov.tr
19. Pugatch RD. Radiologic evaluation in chest malignancies. A review of imaging modalities. Chest 1995;107:294S-7S.
20. Call S, Rami-Porta R, Obiols C, Serra-Mitjans M, Gonzalez- Pont G, Bastús-Piulats R, et al. Repeat mediastinoscopy in all its indications: experience with 96 patients and 101 procedures. Eur J Cardiothorac Surg 2011;39:1022-7.
21. Lardinois D, De Leyn P, Van Schil P, Porta RR, Waller D, Passlick B, et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer. Eur J Cardiothorac Surg 2006;30:787-92.
22. Watanabe H, Okada M, Kaji Y, Satouchi M, Sato Y, Yamabe Y, et al. New response evaluation criteria in solid tumoursrevised RECIST guideline (version 1.1). Gan To Kagaku Ryoho 2009;36:2495-501.
23. Depierre A, Milleron B, Moro-Sibilot D, Chevret S, Quoix E, Lebeau B, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002;20:247-53.
24. Gürsoy S, Usluer O, Ücvet A, Erbaycu AE, Örs Kaya Ş, Koparal H. Long-term survival results of non-small cell lung cancer patients with complete pathological response after neoadjuvant therapy. Turk Gogus Kalp Dama 2016;24:305-11.
25. Cerfolio RJ, Bryant AS, Winokur TS, Ohja B, Bartolucci AA. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg 2004;78:1903-9.
26. Roth JA, Atkinson EN, Fossella F, Komaki R, Bernadette Ryan M, Putnam JB Jr, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998;21:1-6.
27. Kim HK, Cho JH, Choi YS, Zo JI, Shim YM, Park K, et al. Outcomes of neoadjuvant concurrent chemoradiotherapy followed by surgery for non-small-cell lung cancer with N2 disease. Lung Cancer 2016;96:56-62.
28. Rusch VW, Giroux DJ, Kraut MJ, Crowley J, Hazuka M, Winton T, et al. Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol 2007;25:313-8.
29. Kunitoh H, Kato H, Tsuboi M, Shibata T, Asamura H, Ichinose Y, et al. Phase II trial of preoperative chemoradiotherapy followed by surgical resection in patients with superior sulcus non-small-cell lung cancers: report of Japan Clinical Oncology Group trial 9806. J Clin Oncol 2008;26:644-9.
30. Antonoff MB, Hofstetter WL, Correa AM, Bell JM, Sepesi B, Rice DC, et al. Clinical Prediction of Pathologic Complete Response in Superior Sulcus Non-Small Cell Lung Cancer. Ann Thorac Surg 2016;101:211-7.
31. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, et al. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer 2013;14:418-24.
32. Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, et al. Radiation therapy oncology group protocol 02-29: a phase II trial of neoadjuvant therapy with concurrent chemotherapy and full-dose radiation therapy followed by surgical resection and consolidative therapy for locally advanced non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2012;84:456-63.
33. Sonett JR, Suntharalingam M, Edelman MJ, Patel AB, Gamliel Z, Doyle A, et al. Pulmonary resection after curative intent radiotherapy (>59 Gy) and concurrent chemotherapy in non-small-cell lung cancer. Ann Thorac Surg 2004;78:1200-5.